http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
서현주 ( Hyun Joo Suh ),김영호 ( Young Ho Kim ),김지향 ( Ji Hyang Kim ),최용성 ( Yong Sung Choi ),김정 ( Jeong Kim ),이풍렬 ( Poong Lyul Rhee ),김재준 ( Jae J. Kim ),백승운 ( Seung Woon Paik ),이종철 ( Jong Chul Rhee ) 대한장연구학회 2005 Intestinal Research Vol.3 No.2
목적: 조혈모세포 이식 시에 발생하는 급성 설사의 원인은 주로 감염이나 이식편대숙주병으로 알려져 있으나 연구자에 따라 차이가 있으며 아직 국내에서 보고된 바는 없다. 이에 본 연구는 조혈모세포 이식 시에 발생하는 급성 설사의 빈도와 양상, 원인 및 위험 인자들에 관하여 분석하고자 하였다. 대상 및 방법: 1999년 9월부터 2003년 6월까지 삼성서울병원에서 조혈모세포 이식을 시행한 132명의 성인을 대상으로 입원 시부터 이식 후 100일 까지의 의무기록을 분석하였다. 급성 설사는 2일 이상의 기간에 3회 이상의 수양성 설사, 혹은 4회 이상의 묽은 변이 있는 경우로 정의하였다. 결과: 전체 132명 중 95명에서 급성 설사가 발생하였으며 (72%), 총 117예의 급성 설사가 발병하였다. 설사 발생일의 중앙값은 5.9일(-6-93일)이었고 설사 기간의 중앙값은 4.8일(2-71일), 이식 후 처음 3일간의 하루 평균 설사 횟수는 4.0회(3-9회)였다. 이 중 감염이 원인인 경우가 16예(13.7%), 이식편대숙주병이 9예(10.3%)로 나타났다. 추정되는 원인으로는 약제에 의한 것이 19예(12.3%) 점막염이 11예(9.4%), 감염이 5예(4.3%)였고 원인을 모르는 경우가 56예(47.9%)로 가장 많았다. 감염성 설사의 경우 모든 환자의 대변검사에서 Clostridium 독소가 양성으로 나타났다. 설사의 발생은 환자의 성별이나 나이, 기저질환, 이식방법, 거대세포 바이러스 감염예방 유무와는 통계적으로 유의한 관련성을 보이지 않았다. 결론: 조혈모세포 이식 환자에서 급성 설사의 발병율은 72%로 높게 나타났으나 이 중 47%에서 원인이 불명확하였고 이러한 환자들에 대해서 원인규명을 위한 연구가 향후 필요할 것으로 생각한다. Background/Aims: A few study have performed the cause of acute diarrhea in patients undergoing bone marrow transplantation (BMT) so far. We analyzed the prevalence of acute diarrhea after BMT, its etiology and its risk factors. Methods: We retrospectively evaluated records of 132 patients undergoing BMT between September 1999 and Jun 2003. Diarrhea had to get its onset from day of admission to day of 100 posttransplant. Results: 95 patients developed acute diarrhea in 132 patients (72% of incidence). The total episodes of diarrhea were 117. Infection was found in 16 of 117 episodes (13.7%). Acute Graft versus host disease was responsible for 9 of 117 episodes (10.3%). Possible etiology of diarrhea was composed of 19 episodes of medication-induced diarrhea (16.2%), 11 episodes of mucositis (9.4%) and 5 episodes of infection (4.3%). Unknown originated diarrhea were 56 episodes (47.9%). Development of diarrhea was not significantly associated with age, sex, underlying disease, BMT conditions and prophylaxis of CMV virus. Conclusions: Acute diarrhea was common in patients undergoing BMT. However, etiology have not clearly evaluated in half of the cases. Further tests to evaluate etiology of acute diarrhea should be investigated. (Intest Res 2005;3:104-109)
라미부딘과 아데포비어에 순차 내성을 보인 만성 B형 간염 환자에서 라미부딘/아데포비어 병합요법의 항바이러스 효과
서현주 ( Hyun Joo Suh ),박문경 ( Moon Kyung Park ),이향이 ( Hyang Ie Lee ),곽금연 ( Geum Yeon Gwak ),고광철 ( Kwang Cheol Koh ),백승운 ( Seung Woon Paik ),유병철 ( Byung Chul Yoo ),이준혁 ( Joon Hyeok Lee ) 대한소화기학회 2009 대한소화기학회지 Vol.53 No.5
목적: LMV과 ADV의 단독치료에 순차내성을 보인 만성 B형 간염 환자에서 LMV과 ADV의 병합투여 후 항바이러스 효과를 알아보고자 하였다. 대상 및 방법: 1997년부터 2007년 사이 LMV와 ADV에 순차적으로 바이러스 돌파현상을 보였던 만성 B형 간염 환자들을 대상으로 하였고, 이들 중 LMV과 ADV 병합치료를 받은 18명의 환자들을 후향 분석하였다. 결과: LMV-ADV 병합치료 시행 후 추적관찰 기간의 중앙값은 17개월(범위, 6-27)이었다. 병합치료 0, 3, 6, 12, 24개월의 평균 DNA역가는 6.08±0.95, 4.05±1.66, 3.17±1.58, 3.18±2.16, 2.35±1.52 log10 IU/mL였고 전체 18예 중 16예(88.9%)에서 HBV DNA의 역가가 20,000 IU/mL 미만으로 감소하였다. HBeAg의 혈청전환은 단 1예(7.1%)에서만 관찰되었고 12예(66.7%)에서 혈청 ALT가 정상화되었다. 병합치료 12개월과 14개월째 바이러스 반등이 있었던 환자가 2예 있었다. 혈청 ALT는 12예(66.7%)에서 정상으로 감소하였다. 일차치료 실패를 보인 경우는 2예(11.1%)가 있었다. 결론: 이번 연구에서 LMV과 ADV에 순차적으로 내성을 보인 환자들에게 LMV-ADV 병합치료를 시행하고 단기간 추적관찰하였을 때 88.9%에서 효과가 있었다. 이는 다른 항바이러스제의 사용이 여의치 않을 때 LMV-ADV의 병합치료가 도움이 될 수 있음을 보여준다. Background/Aims: The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV consecutively. Methods: A retrospective review was performed in eighteen patients with chronic hepatitis B who developed virologic breakthroughs during LMV-ADV sequential mono-therapy and treated with LMV-ADV combination therapy. Results: The median duration of follow up was 17 months (range, 6-27) after the start of LMV-ADV combination therapy. Mean HBV DNA level in log10 IU/mL was 6.08±0.95, 4.05±1.66, 3.17±1.58, 3.18±2.16, and 2.35±1.52 at 0, 3, 6, 12, and 24 months, respectively. Sixteen patients (88.9%) showed HBV DNA reduction below detection limit (<20,000 IU/mL). HBeAg seroconversion was observed in one patient (7.1%) after 8 months of combination therapy. Virologic breakthrough occurred in only one patient after 21 months of combination therapy. Viral rebound occurred in two patients at 12 months and 14 months of combination therapy. Normalization of serum ALT was achieved in twelve patients (66.7%). Primary non-response was observed in two cases (11.1%). Conclusions: LMV-ADV combination treatment was effective in 88.9% of patients with resistance to LMV and ADV in a short-term follow up. It may be applied as a bridge therapy until another effective antiviral regimen becomes available. (Korean J Gastroenterol 2009;53:305-310)
신동맥 스텐트 삽입술로 치료한 섬유근성 이형성증에 병발한 자발성 신동맥 박리
백현정 ( Hyun Jeong Baek ),김대중 ( Dae Joong Kim ),서현주 ( Hyun Joo Suh ),김민옥 ( Min Ok Kim ),여호명 ( Ho Myoung Yeo ),김정아 ( Jung Ah Kim ),김현진 ( Hyun Jin Kim ),강우헌 ( Woo Heon Kang ),김범 ( Beom Kim ),허우성 ( Woo Seo 대한신장학회 2004 Kidney Research and Clinical Practice Vol.23 No.5
왕찬종,이용준,서현주,김상우,이정윤,김길희,Wang, Chan-Jong,Lee, Yong-Jun,Suh, Hyun-Joo,Kim, Sang-Woo,Lee, Jung-Yoon,Kim, Kil-Hee 大韓建築學會 2014 大韓建築學會論文集 : 構造系 Vol.30 No.10
This study evaluates the flexural performance of reinforced concrete (RC) continuous beams with double beam system (DBS). The DBS method with high-rigidity drop panels in beam-column joints can be expected to decrease the actual span of RC beams. To investigate the effect of drop panels, a total of nine RC continuous beam specimens with various rigidity and length of drop panels is cast and tested under monotonic gravity loads. As a result of test, the specimens with drop panels presented superior flexural behavior and lower deflection under service load compared to those of the specimens without drop panels. Furthermore, the specimens with drop panels showed smaller crack width under service load than compared specimens.
이계주(Gye Ju Rhee),서현주(Hyun Joo Suh),이덕금(Duck Geun Lee),박종범(Jong Bum Park),신광현(Kwang Hyun Shin),황성주(Sung Joo Hwang) 대한약학회 1998 약학회지 Vol.42 No.2
In order to ameliorate disadvantages of buccal ointments and mucoadhesive tablets used for the treatment of aphthosis, a thin mucoadhesive patch containing triamcinolone acetonide was designed and evaluated for the pharmaceutical properties. The adhesive gel layer consisting of Noveon AA-1, hydroxypropylcellulose-M and ethylcellulose N 100, and the protective gel layer of ethylcellulose N 100, Eudragit RSPO and castor oil have been formulated and various properties such as viscosity of drug gel layer, thickness, in vitro adhesion time, adhesive strength, surface pH, content uniformity and drug release are tested. The mean viscosity of drug-containing gel layer was found to increase with increasing amount of Noveon OAA-1 or hydroxypropylcellulose-M. The optimum formulation showed the thickness of 171 mcm, surface pH of 4.6, in vitro adhesion time of 8 hours and adhesive strength of 272.7g/sheet. The drug content of each patch was relatively homogeneous with the value of 273+/-6.77g. Drug release study showed that compared to mucoadhesive tablet, the patch showed a faster drug release. Drug release was delayed by hydroxypropylcellulose-M, but not by ethylcellulose N 100. The patches prepared were nonirritant and the muco adhesion was better than the commercial product (AftachR) on the market. Based on these results, this mucoadhesive patch is expected to be an effective dosage form for the treatment of aphthosis.
Leptospermum Scoparium 수증기 추출물인 마누카 기름의 항균효과
이계주(Gye Ju Rhee),정경수(Kyeong Soo Chung),김은희(Eun Hee Kim),서현주(Hyun Joo Suh),홍남두(Nam Doo Hong) 대한약학회 1997 약학회지 Vol.41 No.1
The antimicrobial activity of Manuka oil, a steam distillate from Leptospermum scoparium, was investigated, and it''s MIC against ten kinds of microorganisms was determined. MICs against bacteria and fungi were measured by means of both two-fold dliution method and agar plate two-fold dilution method, respectively. MICs of Manuka oil against Staphylococcus aureus KCTC 1916 and Micrococcus luteus KCTC 1915, gram-positive microrganisms, were identical as 3.05 mcg/ml, while it''s antibacterial activity against gram-negative microrganisms such as Pseudomonas aeruginosa KCTC 2513, Escherichia coli KCFC 1682, Klebsiella pneunioniae KCTC 2001 or Proteus vulgaris KCTC 2433 was negligible(MIC: > or = 1000 mcg/ml), suggesting a high susceptibility of gram-positive bacteria to Manuka oil. In addition, MIC against Aspergillus niger KCTC 6077 was 24 mcg/ml. and that against the other fungi, Tricophyton mentagrophytes KCTC 1374 and Candida albicans KCTC 1940 was > or + 1000 mcg/ml. When Manuka oil ointment was used in combination with other drugs. i.e.. gentamycin sulfate, chlotrimazol and hydrocortisone acetate, and diphenhydramine HCl and hydrocortisone acetate. it''s antibacterial activity against Staphylococcus aureus KCTC 1916 was higher than Manuka oil ointment or other drugs alone. In conclusion, Manuka oil possesses a selective antibacterial activity against Staphylococcus aureus KCTC 1916, and can be used as a potent antibacterial agent against it.